about
Massive pulmonary embolism in a Lebanese patient doubly heterozygous for MTHFR and Factor V Leiden presenting with syncope and treated with tenecteplase.The role of therapeutic plasma exchange in the catastrophic antiphospholipid syndrome.Sicklemia with multi-organ failure syndrome and thrombotic thrombocytopenic purpura.Thrombotic thrombocytopenic purpura and pregnancy: report of four cases and literature review.Thrombotic thrombocytopenic purpura: 24 years of experience at the American University of Beirut Medical Center.Pregnancy in patients with beta-thalassemia intermedia: outcome of mothers and newborns.Thrombotic thrombocytopenic purpura and bone marrow necrosis associated with disseminated gastric cancer.The hematologic manifestations of the antiphospholipid syndrome.Hematological manifestations of celiac disease.Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major.Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.Paraspinal extramedullary hematopoiesis in patients with thalassemia intermediaA survey of patients with acquired haemophilia in a haemophilia centre over a 28-year period.Cerebral infarction in β-thalassemia intermedia: breaking the silence.Campylobacter fetus pericarditis in a patient with beta-thalassemia: case report and review of the literature.Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overloadPulmonary thromboembolism in beta-thalassemia intermedia: are we aware of this complication?Beta-thalassemia intermedia and non-Hodgkin's lymphoma.Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermediaResponse of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias.Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: results from the ESCALATOR study.Iron overload in thalassemia and sickle cell disease.Splenomegaly, pancytopenia and pregnancy: a case report and review of the literature.Non-Hodgkin disease in beta-thalassemia major.Thalassemia intermedia: revisited.Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemiasA review of the off-label use of recombinant activated factor VII in a developing country tertiary care center.Gaucher disease: different clinical manifestations associated with a rare mutation (R48W) in a Lebanese family.Differences in response to fetal hemoglobin induction therapy in beta-thalassemia and sickle cell disease.Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemiaEffects of divalproex sodium on hemoglobin level.Severe hemophagocytic syndrome developing after treatment initiation for disseminated Mycobacterium tuberculosis: case report and literature review.Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies.Insight onto the pathophysiology and clinical complications of thalassemia intermedia.Iron overload: consequences, assessment, and monitoring.Overview of iron chelation therapy with desferrioxamine and deferiprone.A closer look at paroxysmal nocturnal hemoglobinuria.Resistance to aspirin and clopidogrel therapy.Optimal management of β thalassaemia intermedia.
P50
Q33153719-C6BDD1DB-5525-4DF8-99F2-F626E3E07986Q33216930-18F58A51-8E6C-4272-955D-764ECEEA4A34Q33345707-EA6B7464-CCA0-46DC-A723-603C880E2EFEQ33360484-22BF2A1D-2E92-4484-A050-31701359013DQ33363304-71E5319C-51B8-4F13-A300-52E8790E4614Q33371437-6BF34F64-CC0E-4257-AE29-17AC53DF7A11Q33374911-7113A075-32BB-467D-B433-4AACA4CB3E00Q33379294-B0750B4F-0550-466B-B07C-45636151B4B7Q33402673-154A7FF3-A1EE-4C05-9A8E-4437E4FE3AB9Q33670385-C05B54D6-B107-459F-8062-B3BBF4612941Q33801826-16E2E943-36D9-4FFF-883F-241C13602AF2Q33974681-B5C0C293-3AC1-482E-A89F-398FDE538687Q34106965-B3480F77-D0ED-47C8-A1DF-ECE5BBC672F5Q34363046-1D38EE49-D567-474C-90D6-E273CAE288F0Q34419130-F45C9EBF-111F-4300-A7B4-5E93F5125F18Q34451527-04A73DBF-C9A0-44C9-BB62-AE6E553A28BEQ34764427-72E41A4D-8597-4161-8CB0-E93BF4EFE329Q34981986-A1236683-58C9-4142-A811-E2532ECBA835Q35528614-CA43A036-C46C-475B-B087-2AD2FDD74AB6Q35589756-A38D9F3C-E57D-4563-8A52-D4FB163864C5Q35589769-529D638F-692C-4027-BF5B-047A51063E94Q36104601-9BA1FEBF-C0A8-4EEB-81C8-04A80E13006BQ36132833-B107566C-24C5-4A0B-AC4D-8D35ED472DC9Q36348903-F8D4EBE3-1844-4315-950A-204B783242C9Q36493814-A3E5BF57-E970-4870-9873-E93EBD67DE68Q36524624-F792842A-8CDF-4072-A834-2AE335257D55Q36569047-99B48C65-4639-4ED5-8101-003C6631B9D3Q36653048-2689FE96-2E68-45DB-AE9F-43F18BFD6B23Q36851679-7343AC5A-871D-4C39-9147-ACFD766FA38FQ37254940-08417403-26C8-43AC-A487-39B08420BEDBQ37314834-9648288C-792C-467B-9553-02550B13E7D9Q37405021-CF28A295-3F4B-4A10-A173-9F235DDF32A9Q37486244-3DEA59C9-EE64-4D17-AA91-8F21B0C6FCF2Q37579971-B1B9D6B9-A466-48E9-85F7-1FC0D95FA4EFQ37650433-A8DDE8A3-CCF9-4730-B226-8CB6687650B2Q37650453-5FA293EC-A5B2-44C6-9E0F-3554FFDB7DB4Q37650457-B5201BFD-F731-4A6C-95F9-9413F4567EE1Q37770146-2C42F3B2-D9EA-4089-A4A3-DECC5D83957FQ37807524-C9417720-1740-423F-B9E7-87B0C717136EQ37830724-87236A88-B8A7-4C19-A64F-CB44FD5E5241
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Ali Taher
@ast
Ali Taher
@en
Ali Taher
@es
Ali Taher
@nl
Ali Taher
@sl
type
label
Ali Taher
@ast
Ali Taher
@en
Ali Taher
@es
Ali Taher
@nl
Ali Taher
@sl
prefLabel
Ali Taher
@ast
Ali Taher
@en
Ali Taher
@es
Ali Taher
@nl
Ali Taher
@sl
P1006
P214
P227
P1006
P106
P1153
7005269730
P21
P214
P227
1162519983
P31
P496
0000-0001-8515-2238
P735
P7859
viaf-281846446